Low- but not high-dose FK506 treatment confers atheroprotection due to alternative macrophage activation and unaffected cholesterol levels

Summary

Previous studies showed both proand anti-atherogenic effects of immunosuppressant drug FK506 on atherosclerosis. As these divergent/paradoxical results of FK506 may at least in part be attributable to differences in FK506 dosing, we have, in the current study, assessed dosedependent effects of FK506 on atherosclerotic lesion formation as well as on inflammatory parameters relevant to atherosclerosis. Unlike low-dose FK506, high-dose FK506 did not protect against atherosclerosis in ApoE-/mice. The high-dose induced hypercholesterolaemia, whereas the low-dose did not. Both lowand high-dose FK506 treatment significantly reduced systemic CD3⁺ and CD4⁺CD25⁺ T-cell populations, and showed similar suppression of FoxP3 regulatory T-cell populations. Increased IL-4+ CD4+ T-cells and decreased IgG-MDA-LDL antibody titres pointed to a selective, albeit modest Th2 skewing in the high-dose treatment group, despite the advanced stage of atherosclerosis. Low concentrations of FK506, however, skewed bone marrow-derived macrophage polarisation towards a M2 macrophage phenotype, whereas high concentration did not. A low-dose FK506 treatment regime protected against atherosclerosis by suppressing T-cell activation and favouring (M2) macrophage polarisation. Although a high-dose FK506 treatment effected a similar T-cell suppressive effect, with an even more pronounced shift towards Th2 type immune responses, this did not translate in atheroprotection due to the hypercholesterolaemia and absent M2 skewing.

Keywords

Atherosclerosis - FK506 - immunosuppression - NFAT

^* These authors contributed equally.

• References

• 1 Sewell TJ. et al Inhibition of calcineurin by a novel FK-506-binding protein. J Biol Chem 1994; 269: 21094-2102.
• 2 Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483-510.
• 3 Rao A. et al Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-747.
• 4 Jennings C. et al Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate immunity 2009; 15: 109-120.
• 5 Donners MM. et al Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. Am J Transplant 2005; 05: 1204-1215.
• 6 Matsumoto T. et al Influence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1998; 139: 95-106.
• 7 Wakabayashi H. et al The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. Surg Today 1994; 24: 994-1002.
• 8 Jain AB. et al Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplantation Proc 1991; 23: 928-930.
• 9 Shapiro R. et al Kidney transplantation under FK 506 immunosuppression. Transplantation proceedings 1991; 23: 920-923.
• 10 von der Thusen JH. et al Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001; 103: 1164-1170.
• 11 Smook ML. et al Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice. Clin Exp Immunol 2008; 154: 264-269.
• 12 Bot I. et al Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res 2003; 93: 464-471.
• 13 Muraoka K. et al Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. J Clin Invest 1996; 97: 2433-2439.
• 14 Berman M. et al Lipid metabolism and immunosuppressive therapy in heart transplant recipients. Transplantation Proc 2003; 35: 677.
• 15 Ichimaru N. et al Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417-423.
• 16 Heeneman S. et al Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?. Expert Rev Cardiovasc Ther 2007; 05: 345-364.
• 17 Wu Y. et al FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126: 375-387.
• 18 Miller SA, Weinmann AS. Common themes emerge in the transcriptional control of T helper and developmental cell fate decisions regulated by the T-box, GATA and ROR families. Immunology 2009; 126: 306-315.
• 19 Maue AC, Haynes L. CD4+ T cells and immunosenescence--a mini-review. Gerontology 2009; 55: 491-495.
• 20 Shoenfeld Y. et al Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 2004; 110: 2552-2558.
• 21 Zhou X. et al Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998; 101: 1717-1725.
• 22 Sly LM. et al The role of SHIP in macrophages. Front Biosci 2007; 12: 2836-2848.
• 23 Mantovani A. et al Macrophage diversity and polarization in atherosclerosis: a question of balance. Arteriosclerosis Thromb Vasc Biol 2009; 29: 1419-1423.
• 24 Khallou-Laschet J. et al. Macrophage plasticity in experimental atherosclerosis. PloS one 05: e8852.